Home
JUNS
JUNS News

Latest JUPITER NEUROSCIENCES INC (JUNS) News on February 22, 2025

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

GlobeNewswire

18 days ago

Jupiter Neurosciences Addresses Market Volatility as it Remains Focused on Advancing Clinical and Commercial Milestones

MT Newswires

19 days ago

Jupiter Neurosciences Signs Manufacturing Deal With Catalent Pharma for Jotrol Softgel Capsules

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

GlobeNewswire

19 days ago

Jupiter Neurosciences Announces JOTROL Manufacturing Agreement with Catalent to Support Phase 2a Parkinson’s Trial

MT Newswires

23 days ago

Jupiter Neurosciences, Zina Biopharmaceuticals Collaborate on Phase 2a Parkinson's Disease Study

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

GlobeNewswire

23 days ago

Jupiter Neurosciences Partners with Zina Biopharmaceuticals to Advance Phase 2a Parkinson’s Trial

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

GlobeNewswire

a month ago

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

GlobeNewswire

3 months ago

Jupiter Neurosciences, Inc. Announces Closing of $11 million Initial Public Offering

Share on Social Networks: